04 March 2009 -- Synthon announced today that it has successfully concluded its registration procedures for Levocetirizine. Regulatory clearance has been obtained for Synthon's product in fourteen European countries using decentralized procedures. Registration has been established for 5 mg filmcoated tablets. Synthon's product is a fully bioequivalent version of the oral anti-histamine drug Xyzal.
The details can be read here.
No comments:
Post a Comment